Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)

NCT02756611 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02756611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02756611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
June 22, 2016
Completion date
March 11, 2022
Enrollment
258 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia